Elevated fibroblast growth factor-2 increases tumor necrosis factor-α induced endothelial cell death in high glucose

Journal of Cellular Physiology

Volumn 217, Issue 1, 2008, Pages 86-92

  Clyne, Alisa Morss ^a,b   Zhu, Han ^c   Edelman, Elazer R ^a,d  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b Drexel University   (United States)

^c Massachusetts Institute of Technology Cambridge   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANNEXIN; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 2 ANTIBODY; GLUCOSE; NEUTRALIZING ANTIBODY; PROPIDIUM IODIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL TISSUE; AORTA; APOPTOSIS; ARTICLE; CELL ASSAY; CELL COUNT; CELL CULTURE; CELL CYCLE PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL DEATH; CELL LABELING; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; ENDOTHELIUM CELL; NONHUMAN; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM; ANIMAL; CELL CYCLE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; METABOLISM; NICK END LABELING; PHYSIOLOGY; SWINE;

SUS;

ANIMALS; APOPTOSIS; CELL CYCLE; CELLS, CULTURED; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROBLAST GROWTH FACTOR 2; GLUCOSE; IN SITU NICK-END LABELING; SWINE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 49649115540     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21476     Document Type: Article

References (38)

1. Aggarwal BB. 2003. Signalling pathways of the TNF superfamily: A double-edged sword. Nature Rev Immunol 3:745-756.
2. Anderson HDI, Rahmutula D, Gardner DG. 2004. Tumor necrosis factor-alpha inhibits endothelial nitric-oxide synthase gene promoter activity in bovine aortic endothelial cells. J Biol Chem 279:963-969.
3. Beckman JA, Creager MA, Libby P. 2002. Diabetes and atherosclerosis - Epidemiology, pathophysiology, and management. JAMA 287:2570-2581.
4. Beletskaya IV, Nikonova LV, Beletsky IP. 1997. Cell cycle specificity of Fas-mediated apoptosis in WIL-2 cells. FEBS Lett 412:91-93.
5. Brem H, Tomic-Canic M. 2007. Cellular and molecular basis of wound healing in diabetes. J Clin Invest 117:1219-1222.
6. Cai H, Harrison DG. 2000. Endothelial dysfunction in cardiovascular diseases - The role of oxidant stress. Circ Res 87:840-844.
7. Calver A, Collier J, Vallance P. 1992. Inhibition and stimulation of nitric-oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes. J Clin Invest 90:2548-2554.
8. Cardillo C, Campia U, Bryant MB, Panza JA. 2002. Increased activity of endogenous endothelin in patients with type II diabetes mellitus. Circulation 106:1783-1787.
9. Cooper ME, Bonnet F, Oldfield M, Jandeleit-Dahm K. 2001. Mechanisms of diabetic vasculopathy: An overview. Am J Hypertens 14:475-486.
10. Donato NJ, Perez M. 1998. Tumor necrosis factor-induced apoptosis stimulates p53 accumulation and p2IWAFI proteolysis in ME-180 cells. J Biol Chem 273:5067-5072.
11. Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, Quagliaro L, Ceriello A, Giugliano D. 2002. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans - Role of oxidative stress. Circulation 106:2067-2072.
12. Eswarakumar VP, Lax I, Schlessinger J. 2005. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 16:139-149.
13. Faraco PR, Ledgerwood EC, Vandenabeele P, Prins JB, Bradley JR. 1999. Tumor necrosis factor induces distinct patterns of caspase activation in WEHI-164 cells associated with apoptosis or necrosis depending on cell cycle stage. Biochem Biophys Res Commun 261:385-392.
14. Fiers W, Beyaert R, Boone E, Cornells S, Declercq W, Decoster E, Denecker G, Depuydt B, DeValck D, DeWilde G, Goossens V, Grooten J, Haegeman G, Heyninck K, Penning L, Plaisance S, Vancompernolle K, VanCriekinge W, Vandenabeele P, VandenBerghe W. VandeCraen M, Vandevoorde V, Vercammen D. 1996. TNF-induced intracellular signaling leading to gene induction or to cytotoxicity by necrosis or by apoptosis. J Inflamm 47:67-75.
15. Gardner AM, Johnson GL. 1996. Fibroblast growth factor-2 suppression of tumor necrosis factor alpha-mediated apoptosis requires Ras and the activation of mitogen-activated protein kinase. J Biol Chem 271:14560-14566.
16. Hasegawa G, Nakano K, Sawada M, Uno K, Shibayama Y, Ienaga K, Kondo M. 1991. Possible role of tumor-necrosis-factor and interleukin-I in the development of diabetic nephropathy. Kidney Int 40:1007-1012.
17. Hempel A, Maasch C, Heintze U, Lindschau C, Dietz R, Luft FC, Haller H. 1997. High glucose concentrations increase endothelial cell permeability via activation of protein kinase C alpha. Circ Res 81:363-371.
18. Kado S, Wakatsuki T, Yamamoto M, Nagata N. 2001. Expression of intercellular adhesion molecule-1 induced by high glucose concentrations in human aortic endothelial cells. Life Sci 68:727-737.
19. King KL, Cidlowski JA. 1998. Cell cycle regulation and apoptosis. Annu Rev Physiol 60:601-617.
20. Krady JK, Basu A, Allen CM, Xu YP, LaNoue KF, Gardner TW, Levison SW. 2005. Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes 54:1559-1565.
21. Li J, Zhang YP, Kirsner RS. 2003. Angiogenesis in wound repair: Angiogenic growth factors and the extracellular matrix. Microsc Res Tech 60:107-114.
22. Liu R, Bal HS, Desta T, Behl Y, Graves DT. 2006. Tumor necrosis factor-alpha mediates diabetes-enhanced apoptosis of matrix-producing cells and impairs diabetic healing. Am J Pathol 168:757-764.
23. Lorenzi M, Cagliero E, Toledo S. 1985. Glucose toxicity for human-endothelial cells in culture - Delayed replication, disturbed cell-cycle, and accelerated death. Diabetes 34:621-627.
24. Martin A, Komada MR, Sane DC. 2003. Abnormal angiogenesis in diabetes mellitus. Med Res Rev 23:117-145.
25. Messmer UK, Briner VA, Pfeilschifter J. 2000. Basic fibroblast growth factor selectively enhances TNF-alpha-induced apoptotic cell death in glomerular endothelial cells: Effects on apoptotic signaling pathways. J Am Soc Nephrol 11:2199-2211.
26. Michiels C. 2003. Endothelial cell functions. J Cell Physiol 196:430-443.
27. Morss AS, Edelman ER. 2007. Glucose modulates basement membrane fibroblast growth factor-2 via alterations in endothelial cell permeability. J Biol Chem 282:14635-14644.
28. Nugent MA, Iozzo RV. 2000. Fibroblast growth factor-2. Int J Biochem Cell Biol 32:115-120.
29. Pober JS, Gimbrone MA, Lapierre LA, Mendrick DL, Fiers W, Rothlein R, Springer TA. 1986. Overlapping patterns of activation of human-endothelial cells by interleukin-I, tumor-necrosis-factor, and immune interferon. J Immunol 137:1893-1896.
30. Robaye B, Mosselmans R, Fiers W, Dumont JE, Galand P. 1991. Tumor-necrosis-factor induces apoptosis (programmed cell-death) in normal endothelial-cells in vitro. Am J Pathol 138:447-453.
31. Royall JA, Berkow RL, Beckman JS, Cunningham MK, Matalon S, Freeman BA. 1989. Tumor necrosis factor and interleukin I-alpha-increase vascular endothelial permeability. Am J Physiol 257:L399-L410.
32. Satoh J, Yagihashi S, Toyota T. 2003. The possible role of tumor necrosis factor-alpha in diabetic polyneuropathy. Exp Diabesity Res 4:65-71.
33. Shih SC, Stutman O. 1996. Cell cycle-dependent tumor necrosis factor apoptosis. Cancer Res 56:1591-1598.
34. Tsilibary E. 2003. Microvascular basement membranes in diabetes mellitus. J Pathol 200:537-547.
35. Varfolomeev EE, Ashkenazi A. 2004. Tumor necrosis factor: An apoptosis JuNKie? Cell 116:491-497.
36. Werner S, Grose R. 2003. Regulation of wound healing by growth factors and cytokines. Physiol Rev 83:835-870.
37. Yoshida S, Ono M, Shono T, Izumi H, Ishibashi T, Suzuki H, Kuwano M. 1997. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol 17:4015-4023.
38. Zimering MB, Eng J. 1996. Increased basic fibroblast growth factor-like substance in plasma from a subset of middle-aged or elderly male diabetic patients with microalbuminuria or proteinuria. J Clin Endocrinol Metab 81:4446-4452.